Zentalis Pharmaceuticals (ZNTL)
(Delayed Data from NSDQ)
$2.94 USD
-0.02 (-0.68%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $2.94 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.94 USD
-0.02 (-0.68%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $2.94 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Zacks News
Biotech Stock Roundup: GILD, NUVL Stocks Surge on Study Data, MRNA Down on Updates
by Zacks Equity Research
Gilead Sciences and Nuvalent are in the spotlight following positive updates on key candidates.
Zentalis Stock Up as FDA Lifts Partial Hold on Cancer Drug Studies
by Zacks Equity Research
ZNTL stock gains as the FDA lifts clinical hold on studies of its lead candidate, azenosertib, which is being developed for different cancer indications.
Zentalis (ZNTL) Plunges More Than 70% in 3 Months: Here's Why
by Zacks Equity Research
The recent regulatory setbacks related to Zentalis' (ZNTL) lead pipeline candidate, azenosertib, weigh heavily on the stock.
Biotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
by Zacks Equity Research
Intra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates, respectively.
Zentalis (ZNTL) Tanks After FDA Puts 3 Cancer Studies on Hold
by Zacks Equity Research
Zentalis' (ZNTL) three studies evaluating azenosertib for three different cancer indications face the FDA's partial clinical hold following the death of two patients.
Wall Street Analysts Think Zentalis Pharmaceuticals, Inc. (ZNTL) Could Surge 136.44%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 136.4% upside potential for Zentalis Pharmaceuticals, Inc. (ZNTL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Down -19.06% in 4 Weeks, Here's Why You Should You Buy the Dip in Zentalis Pharmaceuticals, Inc. (ZNTL)
by Zacks Equity Research
Zentalis Pharmaceuticals, Inc. (ZNTL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
What Makes Zentalis Pharmaceuticals, Inc. (ZNTL) a New Buy Stock
by Zacks Equity Research
Zentalis Pharmaceuticals, Inc. (ZNTL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Believe Zentalis Pharmaceuticals, Inc. (ZNTL) Could Rally 95.67%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 95.7% upside potential for Zentalis Pharmaceuticals, Inc. (ZNTL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Can Zentalis Pharmaceuticals, Inc. (ZNTL) Climb 170% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 170.4% in Zentalis Pharmaceuticals, Inc. (ZNTL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zentalis Pharmaceuticals, Inc. (ZNTL) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Zentalis Pharmaceuticals, Inc. (ZNTL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Does Zentalis Pharmaceuticals, Inc. (ZNTL) Have the Potential to Rally 129% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 128.7% upside potential for Zentalis Pharmaceuticals, Inc. (ZNTL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Why Zentalis Pharmaceuticals (ZNTL) Might Surprise This Earnings Season
by Zacks Equity Research
Zentalis Pharmaceuticals (ZNTL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Here's Why Zentalis Pharmaceuticals, Inc. (ZNTL) is Poised for a Turnaround After Losing 50% in 4 Weeks
by Zacks Equity Research
The heavy selling pressure might have exhausted for Zentalis Pharmaceuticals, Inc. (ZNTL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Why Earnings Season Could Be Great for Zentalis (ZNTL)
by Zacks Equity Research
Zentalis (ZNTL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.